Molecular alterations for targeted therapy in metastatic gynecologic cancer
- Prosjektnummer
- 911577
- Ansvarlig person
- Maria Th Barøy Ræder
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Forskerutdanning - postdoc
- Helsekategori
- Cancer
- Forskningsaktivitet
- 5. Treatment Developement
Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.
Gynecol Oncol 2014 Sep;134(3):599-606. Epub 2014 jul 1
PMID: 24995579
Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.
PLoS One 2013;8(2):e54873. Epub 2013 feb 5
PMID: 23393560
Lack of estrogen receptor-a is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.
Clin Cancer Res 2013 Mar 1;19(5):1094-105. Epub 2013 jan 14
PMID: 23319822
KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.
Br J Cancer 2012 Dec;107(12):1997-2004. Epub 2012 okt 25
PMID: 23099803
Lipocalin 2 expression is associated with aggressive features of endometrial cancer.
BMC Cancer 2012;12():169. Epub 2012 mai 6
PMID: 22559235
Loss of GPER identifies new targets for therapy among a subgroup of ERa-positive endometrial cancer patients with poor outcome.
Br J Cancer 2012 May;106(10):1682-8. Epub 2012 mar 13
PMID: 22415229
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
Nat Med 2011 Sep;17(9):1116-20. Epub 2011 aug 7
PMID: 21822287
High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer.
Br J Cancer 2011 Mar;104(6):921-6. Epub 2011 feb 22
PMID: 21343929
- Helga Birgitte Salvesen Leder av forskningsgruppe
- Maria B Ræder Postdoktor
- Helge Salvesen Leder av forskningsgruppe
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest